A conserved intratumoral regulatory T cell signature identifies 4-1BB as a pan-cancer target
Zachary T. Freeman(Johns Hopkins University), Charles G. Drake(Johns Hopkins Medicine), Linda A. Snyder(Springhouse), Mark Selby(Bristol-Myers Squibb (United States)), Jingyi Zhai(University of Michigan), Alexander T. Pearson(University of Chicago), Alyza Skaist(Sidney Kimmel Comprehensive Cancer Center), Alan J. Korman(Bristol-Myers Squibb (United States)), Thomas R. Nirschl(Johns Hopkins University), John Engelhardt(Bristol-Myers Squibb (United States)), Scott A. Tomlins(University of Michigan), Ruth Y. Lan(Bristol-Myers Squibb (Germany)), Christina M. Kochel(Johns Hopkins University), Robert J. Johnston(Bristol-Myers Squibb (United States)), Srinivasan Yegnasubramanian(Johns Hopkins Medicine), Daniel H. Hovelson(Michigan Medicine), Hui Jiang(University of Michigan), Ali Ghasemzadeh(Johns Hopkins University), Anuj Gupta(Johns Hopkins University), Sarah J. Wheelan(Sidney Kimmel Comprehensive Cancer Center)
Cited by 133
Related Papers
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
|New England Journal of Medicine|2012|12.6k
Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
|New England Journal of Medicine|2012|8k
Nivolumab plus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2013|4.2k
Integrative Clinical Genomics of Advanced Prostate Cancer
|Cell|2015|3.6k
Deep learning can predict microsatellite instability directly from histology in gastrointestinal cancer
|Nature Medicine|2019|1.4k